Cargando…

Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis

BACKGROUND: Current heart failure (HF) guidelines recommend titrating angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) and beta-blockers (BBs) to target doses used in pivotal placebo-controlled randomized controlled trials (RCTs). Despite a number of RCTs compari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turgeon, Ricky D., Kolber, Michael R., Loewen, Peter, Ellis, Ursula, McCormack, James P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394936/ https://www.ncbi.nlm.nih.gov/pubmed/30817783 http://dx.doi.org/10.1371/journal.pone.0212907

Ejemplares similares

Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis
por: Liu, Feng, et al.
Publicado: (2014)

Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
por: Tsujimoto, Tetsuro, et al.
Publicado: (2018)

Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta‐blockers
por: Varian, Kenneth D., et al.
Publicado: (2020)

The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction
por: Xu, Xizhen, et al.
Publicado: (2019)

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2021)

Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients
por: Cho, Min Ae, et al.
Publicado: (2020)

Myocardial strain to identify benefit from beta‐blockers in patients with heart failure with reduced ejection fraction
por: Park, Chan Soon, et al.
Publicado: (2022)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Early prophylaxis of cardiomyopathy with beta-blockers and angiotensin receptor blockers in patients with Duchenne muscular dystrophy
por: Lee, Heirim, et al.
Publicado: (2022)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

Use of angiotensin receptor blocker is associated with improved 1 year mortality in heart failure with mid‐range ejection fraction
por: Wang, Bin, et al.
Publicado: (2021)

Mechanisms by which angiotensin-receptor blockers increase ACE2 levels
por: Ferrario, Carlos M., et al.
Publicado: (2020)

Aggressive beta-blocker titration in stabilized acute heart failure patients with low left ventricular ejection fraction
por: Waranugraha, Yoga, et al.
Publicado: (2021)

Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction
por: Gilstrap, Lauren G., et al.
Publicado: (2017)

Association between prognosis and the use of angiotensin‐converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction
por: Sunaga, Akihiro, et al.
Publicado: (2022)

Beta-Blockers in Heart Failure with Preserved Ejection Fraction: Could Their Use Be Vindicated as an Acceptable Option in the Future Treatment Guideline?
por: Cho, Jae Yeong
Publicado: (2019)

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
por: Chae, Young Kwang, et al.
Publicado: (2013)

The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases
por: Strauss, Martin H., et al.
Publicado: (2021)

Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers
por: Chao, Chia-Ter
Publicado: (2011)

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
por: Liu, Tao, et al.
Publicado: (2023)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Genome-Wide Association Study of Beta-Blocker Survival Benefit in Black and White Patients with Heart Failure with Reduced Ejection Fraction
por: Luzum, Jasmine A., et al.
Publicado: (2023)

Effects of beta-blocker withdrawal in patients with heart failure with preserved ejection fraction: A protocol for systematic review and meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2023)

Beta-blocker management in patients admitted for acute heart failure and reduced ejection fraction: a review and expert consensus opinion
por: Schurtz, Guillaume, et al.
Publicado: (2023)

Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: Results from The Korea Acute Heart Failure (KorAHF) Registry
por: Kim, Sung-Hwan, et al.
Publicado: (2018)

Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction
por: Ko, Dennis, et al.
Publicado: (2019)

ACE Inhibitor/Angiotensin Receptor Blocker Use Patterns in Advanced CKD and Risk of Kidney Failure and Death
por: Arora, Nayan, et al.
Publicado: (2020)

Association between the beta‐blockers, calcium channel blockers, all‐cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta‐analysis of randomized controlled trials
por: Wu, Mingming, et al.
Publicado: (2023)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

Beta‐blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2017)

Beta-blockers in sepsis
por: Singer, Mervyn
Publicado: (2019)

Beta Blockers and Melanoma
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Impact of left ventricular ejection fraction on the effect of renin-angiotensin system blockers after an episode of acute heart failure: From the KCHF Registry
por: Yoshikawa, Yusuke, et al.
Publicado: (2020)

Treatment of heart failure with ACE inhibitors and beta-blockers: What is next? Aldosterone receptor antagonists?
por: van der Horst, Iwan C. C., et al.
Publicado: (2007)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
por: Chatterjee, Saurav, et al.
Publicado: (2013)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
Publicado: (2013)

Curative effect of β-blocker on various ejection fractions of patients with atrial fibrillation
por: Cao, Wei, et al.
Publicado: (2019)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0n8og7dhauounu0nmsdtun35mi